Jul 31, 2025 • Benzinga
SOMEWHAT-BULLISH
BioCryst Announces Charlie Gayer to Succeed Jon Stonehouse as Chief Executive Officer Upon his Retirement in December - BioCryst Pharma ( NASDAQ:BCRX )
RESEARCH TRIANGLE PARK, N.C., July 31, 2025 ( GLOBE NEWSWIRE ) -- BioCryst Pharmaceuticals, Inc. BCRX today announced that its president and chief executive officer, Jon Stonehouse, has informed the board of directors of his intention to retire on December 31, 2025.
Jul 31, 2025 • GlobeNewswire
SOMEWHAT-BULLISH
BioCryst Announces Charlie Gayer to Succeed Jon Stonehouse as Chief Executive Officer Upon his Retirement in December
RESEARCH TRIANGLE PARK, N.C., July 31, 2025 ( GLOBE NEWSWIRE ) -- BioCryst Pharmaceuticals, Inc. ( Nasdaq: BCRX ) today announced that its president and chief executive officer, Jon Stonehouse, has informed the board of directors of his intention to retire on December 31, 2025.
Jul 31, 2025 • Zacks Commentary
SOMEWHAT-BEARISH
New Strong Sell Stocks for July 31st
CELZ, GRFS and WHR have been added to the Zacks Rank #5 (Strong Sell) List on July 31, 2025.
Jul 09, 2025 • Benzinga
SOMEWHAT-BULLISH
Verona Pharma, Rhythm Pharmaceuticals, AES And Other Big Stocks Moving Higher On Wednesday - First Majestic Silver ( NYSE:AG ) , AES ( NYSE:AES )
U.S. stocks were higher, with the Dow Jones index gaining around 0.1% on Wednesday. Shares of Verona Pharma plc VRNA rose sharply during Wednesday's session after Merck announced it will acquire the company in a $10 billion deal.
Jun 27, 2025 • Zacks Commentary
SOMEWHAT-BULLISH
Will Strong Asceniv Sales Drive ADMA Biologics Further?
ADMA rides on record Asceniv sales and FDA-backed yield boost, but valuation concerns and EPS downgrades cloud its outlook.
Jun 16, 2025 • Zacks Commentary
NEUTRAL
ADMA Looks to Expand Asceniv's Label: Will This Boost Sales?
ADMA surges on soaring Asceniv demand and eyes pediatric label expansion to widen its immunodeficiency treatment reach.